{"name":"Scilex Pharmaceuticals, Inc.","slug":"scilex-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lidocaine patch 1.8%","genericName":"Lidocaine patch 1.8%","slug":"lidocaine-patch-1-8","indication":"Postherpetic neuralgia (PHN)","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SP-102","genericName":"SP-102","slug":"sp-102","indication":"Chronic pain","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ZTlido","genericName":"ZTlido","slug":"ztlido","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Lidocaine patch 1.8%","genericName":"Lidocaine patch 1.8%","slug":"lidocaine-patch-1-8","phase":"marketed","mechanism":"Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application.","indications":["Postherpetic neuralgia (PHN)","Localized neuropathic pain"],"catalyst":""},{"name":"SP-102","genericName":"SP-102","slug":"sp-102","phase":"phase_3","mechanism":"SP-102 is a synthetic version of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.","indications":["Chronic pain"],"catalyst":""},{"name":"ZTlido","genericName":"ZTlido","slug":"ztlido","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPc3NEdVhOTFlFQ0NyS2E4aHR3UGNiVjBCMjZpZTNUSm5VQnNWSDgyTlFDZTRoNzh5aWdlZkdGczc3TzZhbE5tQlpYWGpablZvZHpYVUg1WVBueFpsMGs5Ql81T01ScFBYWVF0ZUpoNHRYR0hvVERSMFNBejcwQ1ZUcVlSWG5RZ0JFRUY2aGpENTFlOUEwb1VPVHU3NXI3Z2hFLVBNZ2UyN3FseVFzSXVSakpRWHloR3o4bk5LVE1zWkw4cF9KT3E4OHJCRXFlWTZUbzhkb0VnT2J0T0RDeUNnXzZSV0lBZ1BGXzUzVWNpb25YZUR3TUZCQkhCR1l0T25wV2lEYkN5dkRWOGt4WU5yQmtR?oc=5","date":"2026-01-07","type":"regulatory","source":"PR Newswire","summary":"Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - PR Newswire","headline":"Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Divid","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNQVJMc2Zlb01ZckNEdEJ4bUF6bFlmUldkRGgyVGpOQmNEWnpQX3EtWTA2Qm5iWjFTZzVzbDFheXo1amhaeUk3bnJxeWYyb2JJd040RmNTc3QyLUp2ZkFEcmpoRjJNVmNLUDBzc3dUc1ZqajhmSTVsaHh6SHhZMVV3cU12TWlxYm13cFZtOXlDWnVnRlhKZWRvQWZ6SDhldEtnXzR2ZG1oMGY3dHI5LTdiVzdtMksyX2NkSHpYSllPQ2xJQ1VLY0VWSEdZMk1Uc3FPRXdQX0NPZzdUX1NaUU5yTg?oc=5","date":"2025-10-01","type":"pipeline","source":"Quiver Quantitative","summary":"Scilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 Million - Quiver Quantitative","headline":"Scilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcFlGQUJEVU81RTRQTUEwVnpfYkVDVkRGNEFjajdfclZ6dEtiLS03amtXSjllYzNybk0zTUxvUWp2T3RXOU1NZW96ZEdiRGpKZDR3cXNwRG5qc1dSbXdNWTBPNm9acmExQ0RjZVhRbDN5dDNXWWZodnFfOEY5bHk3d0JrbzEyY2FxRWlCWWc3VkwzUlVDS0M1VmZma3daTnV4V25YRkJuQVRaQTd5djMwSnl0YURyLVZETklNRllhdw?oc=5","date":"2025-09-25","type":"deal","source":"stocktitan.net","summary":"$200M Bitcoin Deal: Biotech Scilex Trades Semnur Pharma Shares in Groundbreaking Crypto Exchange - stocktitan.net","headline":"$200M Bitcoin Deal: Biotech Scilex Trades Semnur Pharma Shares in Groundbreaking Crypto Exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOWTVTT1cxZDJrX3JFc2FsRmtVV0VhTk83Y0R2NHk5TGxEOGw4REMwaXNmZUIwa0JmRVFfTUpZcS0yQ2ZHTzhzNVhlUHFMLV9qNndKZGRhdjFoV1Rxc1ZfT0daejFQX1hzM05kbi1CY2pFUXdWRVpMRmg2MVJiTkJtN3BPUEo2Wjc1dHBRTktsWjU2dw?oc=5","date":"2025-09-23","type":"pipeline","source":"Yahoo Finance","summary":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously ","headline":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”),","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-04","type":"pipeline","source":"GlobeNewswire","summary":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned - GlobeNewswire","headline":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPVVYwekczQWJrRjhlWHh3SDJnTk9ock8zNF9MYzZUTEJVNUV1NjlLWDBwUnhRMkxTNUh1dGVvcllKd1pmQzN5eHU4LWVWSHNGWEZwMmR6QXNfN3V3WXNGb2owOFJGdS1mV0xqR0hDc1BxNlF2TVRuVlJ1YnZKeklVdE5wN0M1c1FZbTN0ZVJjVnp6LWtia2Qxd1BsY3dzTWp5YjN1c3VJbTI3cGh0VG12ejZhVU1hMU5Zb0t6cktyMG5KUDVLNjh2VHR0NEFaSHc?oc=5","date":"2025-08-21","type":"deal","source":"Stocktwits","summary":"Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside - Stocktwits","headline":"Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNalpWblljb3IySVVrWTFDY1BybzVGTVZGbTBaeXF0QjhpNDV4dUpuSmdaTzZjajRPcUFudmRGS2E3QWZvR0UwXzdlSmRRZTQxdWo1Qm1SMDVPSWVqYW9QM3hCX05telBHV1FXeUo4dDdSNVdkSUYta01GeFBUSGtoR2kwcHpZd2x1M0dNLXBuUWZhTTQ?oc=5","date":"2024-12-16","type":"pipeline","source":"bizjournals.com","summary":"Palo Alto pharmaceutical company secures $17M - bizjournals.com","headline":"Palo Alto pharmaceutical company secures $17M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZnZGWE9SenZaT0hKLVVNd2tnZEE2SDdLZ2ZqcVVJMFlnR0l6ZUVFR3hVU0hBNXNGOVFZa1NvNnVkckVYQ3lYNENFNGlPc1I0TnVqODcwUFduNURxM2ZaTXF0WldWWE1maEtEcEsxX1RYVE9EcG11Mm85OGRvWG94aEczV2F6TWU2ODBzdS1pQVZrT1JPWlNXcVJINThqZUljVkktZlVwQzgxN2t4U192eDRCNTZBYzJ4ZFo1ekJR?oc=5","date":"2024-10-16","type":"pipeline","source":"Fierce Pharma","summary":"Scilex Holding looks to separate Scilex Pharma through potential spinout, IPO - Fierce Pharma","headline":"Scilex Holding looks to separate Scilex Pharma through potential spinout, IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNTFRfWXhoMVdZMTZJMUg5Z19pWjJSRDIwLWRfVk5EMTk4T29pTUQ2cE9TdENuWjJCOGtDeklPRHZQaGdHOUZMS1ZiMENHTUlDeEdhUTVNTlFwYXhYbk1iRnhrekMxRDc1RmJ0MThKS2p1ejhUd3BOMVgwZGJlR2Y0elo5Z1FuVmxOejZJUw?oc=5","date":"2024-10-16","type":"pipeline","source":"Yahoo Finance","summary":"Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by w","headline":"Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the V","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZUQwZmxNLVUwTklMNnFWemFFWVN6ZjRPajFXNUMtNlk1V0VkNGdkdFU3aHVuVk5yYzRpYWJrQlBPdGRrQjlPZkRLNVFNc050SnE4RjRlWUpKOE9fLUZFNGh6X3h4bjRmVzhrWmZXeFItX0VmaVNRNDVBV3FzMG1GWnp6VlR4Q192TlQ1cElMdkhSU0cxcnJmcEpLU0w3RDJLZFdsMTNoek53RkNubXd0dTU0YlpmOElHZ3ctT3ZEZjhfR2tRd284dWtPblhsVjJwYmc?oc=5","date":"2024-10-07","type":"pipeline","source":"PR Newswire","summary":"Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire","headline":"Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNU2h5TEljT1g3UFU0cl8xT3JqTWplR2w3M0JQdnlCN3RGX2h6M3g2WEdnY3RhbEJ5YWJWdzJXY1ZiLUZhU2hDVFNfZW5USzVqT2dyeGFFT0xLVTUtWGcxaG9yekJlWkk2U3JvRXNRMXRCOHMyQURZZUFFWllxUXpELW01UFVHdmtLQUk4RHBKLTBrTzFUbkVTZjJPdkk3Q2dyRlprQzNhdVFtamg0bDQ1M18yb1B4S1J0ZkFyckhn?oc=5","date":"2024-09-03","type":"deal","source":"Fierce Pharma","summary":"Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect - Fierce Pharma","headline":"Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNMURmUWdvbHJudE1ISE9BOFV4SUJhNE1EYTFLNjNYaUEwNnJmZ19XNEZKWHBua3ZzaXpDelN3OGthb1gtZnZfdmJ6d2IxVTlQaWtLTlN4RkZ1N21ocVFFd040Y1VNN1Vob2F4cXlGMUFRQUg4a1lLOVJ2aTNBb1VKcExFTXRlTnlMWF9lMWxWN3l0VkhHcnB0NlNlek44aUx6SFMxNWZQZ1NuOFZ6bXllQ0lXQmVFY1BGbHBNQ2c3aWhoMnd0eTZEcDNJOUlIbUxVTFFZQ1JDS3JJX1ZSYkM2bTV5UjFERDB0ZFhGaGlEd2VQQXJybnotZ1FRb3p1cXd3M3dlcw?oc=5","date":"2024-02-28","type":"pipeline","source":"BioSpace","summary":"Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S. - BioSpace","headline":"Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of T","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}